diabetes Archives

AppWizard

May 27, 2026

Urgent product correction for MiniMed Android App

Medtronic has issued an Urgent Product Correction for the MiniMed Mobile App for Android, version 3.2.0, due to a critical issue that may cause unexpected disconnection from the insulin pump. Users are advised to upgrade to version 3.2.1 or higher to resolve this problem and improve app functionality. The updated version can be downloaded from the Google Play Store, and users can check for updates by navigating to Manage apps & devices. Medtronic provides a 24-Hour Technical Support line at 1800 777 808 for assistance.

AppWizard

December 11, 2025

Tandem Mobi’s Android App Receives FDA Approval

On November 10, 2025, the Tandem Mobi insulin pump system received FDA approval for compatibility with Android smartphones, expanding access to its mobile app for both Apple and Android users. The Tandem Mobi is an automated insulin delivery system that adjusts insulin doses based on real-time blood sugar data from a continuous glucose monitoring system. It utilizes Control-IQ+ technology, which has shown users achieving up to 79 percent time in range during the day and 90 percent overnight. The mobile app allows users to manage diabetes directly from their smartphones and facilitates secure communication with healthcare providers. Nationwide access to the Tandem Mobi system is expected to begin in early 2026, with a limited release in December 2025, and the Android app will be available on the Google Play Store for select smartphone models.

AppWizard

November 22, 2025

Why Tandem Diabetes Care (TNDM) Is Up 14.3% After FDA Clears Android App for Mobi System and What’s Next

Tandem Diabetes Care has received FDA clearance for the Android version of the Tandem Mobi mobile app, set for limited release in December 2025 and broader availability in early 2026. This app will enhance accessibility to Tandem’s automated insulin delivery system for users with compatible Android smartphones. The company plans to launch the t:slim X2’s integration with Abbott’s FreeStyle Libre 3 Plus CGM sensor in October 2025, aiming to attract more continuous glucose monitoring users. Analysts project Tandem Diabetes Care could achieve .2 billion in revenue and .4 million in earnings by 2028, assuming a 7.5% annual revenue growth rate. Fair value estimates for the stock range from .64 to .57 per share, indicating a potential downside from its current market price.